Haisco Pharmaceutical has entered into an exclusive licensing agreement with AbbVie. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialise novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.

The program includes multiple compounds designed to address pain-related indications. These compounds are currently at various development stages in China, ranging from preclinical to phase 1 clinical development.

"This collaboration is highly aligned with our international development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, Chief Executive Officer, Haisco. "By partnering with a global biopharmaceutical leader such as AbbVie, Haisco aims to accelerate the global development of innovative pain therapies and deliver high-quality treatment options to patients worldwide."

The collaboration strengthens Haisco's global presence and pipeline by leveraging AbbVie's development and commercialisation capabilities, as well as its recognised expertise in neuroscience.

The company will receive an upfront payment of USD 30 million and is eligible to receive up to USD 715 million in aggregate development, regulatory, and commercial milestone payments. In addition, it is eligible to receive tiered royalties on future net sales.